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Abstract
Background: Patients with chronic fatigue syndrome experience extreme fatigue, which often leads to substantial
limitations of occupational, educational, social and personal activities. Currently, there is no consensus regarding the
treatment. Patients try many different therapies to overcome their fatigue. Although there is no consensus,
cognitive behavioural therapy is seen as one of the most effective treatments. Little is known about multidisciplinary
rehabilitation treatment, a combination of cognitive behavioural therapy with principles of mindfulness, gradual
increase of activities, body awareness therapy and pacing. The difference in effectiveness and cost-effectiveness
between multidisciplinary rehabilitation treatment and cognitive behavioural therapy is as yet unknown. The FatiGo
(Fatigue-Go) trial aims to compare the effects of both treatment approaches in outpatient rehabilitation on fatigue
severity and quality of life in patients with chronic fatigue syndrome.
Methods: One hundred twenty patients who meet the criteria of chronic fatigue syndrome, fulfil the inclusion
criteria and sign the informed consent form will be recruited. Both treatments take 6 months to complete.
The outcome will be assessed at 6 and 12 months after the start of treatment. Two weeks after the start of
treatment, expectancy and credibility will be measured, and patients will be asked to write down their
personal goals and score their current performance on these goals on a visual analogue scale. At 6 and
14 weeks after the start of treatment, the primary outcome and three potential mediators—self-efficacy, causal
attributions and present-centred attention-awareness—will be measured. Primary outcomes are fatigue severity
and quality of life. Secondary outcomes are physical activity, psychological symptoms, self-efficacy, causal
attributions, impact of disease on emotional and physical functioning, present-centred attention-awareness, life
satisfaction, patient personal goals, self-rated improvement and economic costs. The primary analysis will be
based on intention to treat, and longitudinal analysis of covariance will be used to compare treatments.
Discussion: The results of the trial will provide information on the effects of cognitive behavioural therapy
and multidisciplinary rehabilitation treatment at 6 and 12 months follow-up, mediators of the outcome,
cost-effectiveness, cost-utility, and the influence of treatment expectancy and credibility on the effectiveness
of both treatments in patients with chronic fatigue syndrome.
Trial registration: Current Controlled Trials ISRCTN77567702.
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Background
In chronic fatigue syndrome (CFS), patients experience
extreme fatigue that is medically unexplained. Many
patients feel limited in their daily activities, and are not
able to work at all or as much as they did before their
CFS started [1]. Social and leisure activities are reduced
in most patients, and quality of life is low [2].
Of the current definitions of CFS [3], we use the defin-
ition of the US Centers for Disease Control and Prevention
(CDC-94): a persistent or relapsing unexplained fatigue, of
new or definite onset and lasting for at least 6 months, in
which fatigue is not the result of an organic disease or on-
going exertion. Rest does not alleviate the fatigue, and
there is substantial limitation of occupational, educational,
social and personal activities. To support the diagnosis,
four or more of the following symptoms should be present
for more than 6 months: impaired memory or concentra-
tion, sore throat, tender cervical or axillary lymph nodes,
muscle pain, pain in several joints, new headaches, unre-
freshing sleep or malaise after exertion [4]. Three studies
from the UK and the USA, using this definition, show
prevalence rates between 0.23 and 0.50% [5-7]. In The
Netherlands approximately 30,000-40,000 patients suffer
from CFS [8].
The pathophysiology of CFS is unclear. Researchers
have considered somatic (e.g. viral infection, dysfunction
of the central nervous system, immune dysfunction and
neuroendocrine responses) and psychosocial hypotheses.
A commonly used hypothesis relates CFS to stress.
According to Van Houdenhove [9], patients have a
reduced effort tolerance, which might be interpreted as a
fundamental failure of the stress system after a period of
severe or prolonged physical and/or psychosocial stress
in vulnerable individuals. The failure of the stress system
may lead to disturbances in the nervous, hormone and
immune systems. Many studies have tried to investigate
different parts of these systems, but the precise mechan-
isms are still unclear [3,10]. Although there is no consen-
sus on the pathophysiology of CFS, most researchers and
clinicians believe that the aetiology is multifactorial
[3,11].
Different predisposing, precipitating and perpetuating
factors play an important role in the aetiology of CFS
[3]. Lifestyle and personality characteristics like neuroti-
cism and introversion are examples of predisposing fac-
tors for developing CFS [3,12]. Acute physical of
psychological stress are precipitating factors that may
trigger the onset of CFS [13]. Cognitions, beliefs and
attributions about complaints and behavioural factors
such as persistent avoidance of activities are associated
with an increase of symptoms [14]. Other perpetuating
factors are a strong belief in a physical cause of the ill-
ness, a strong focus on physical sensations and poor
sense of control over the complaints. Social processes,
for example lack of social support, also contribute to
the perpetuation of CFS [15].
Although many patients suffer from CFS, many parts of
this syndrome are still unclear and need further research
in order to understand the pathophysiology and aetiology,
and to improve and customise treatment to individuals in
accordance with the different pathophysiology and/or
aetiology.
Relevance
Many studies have investigated the effects of different
treatments that are targeted towards one or two aspects
of the complaints. Little is known about treatments that
are targeted towards more aspects of the complaints and
combine different interventions in multidisciplinary set-
tings. Although a few treatments that are targeted to-
wards one or two aspects of the complaints have
significant effect on fatigue severity and quality of life,
no consensus exists on the treatment of patients with
CFS. Many patients try different therapies to overcome
their fatigue, varying from pharmacological treatment
(for example immunoglobulin therapy and fludrocorti-
sone therapy) to non-pharmacological treatments (for
example massage therapy and osteopathy). Several
reviews [3,10,16-18] compare different treatments. Im-
mediately post-treatment, cognitive behavioural therapy
(CBT) and graded exercise therapy (GET) are the only
interventions found to be beneficial in reducing the se-
verity of fatigue symptoms when compared with usual
care [18,19]. At medium term (with a maximal of
14 months after baseline), CBT is also more effective
than usual care in reducing fatigue severity [18]. The re-
view by Edmonds et al. [19] showed two studies that
found no significant difference between GET and treat-
ment as usual/relaxation in the severity of fatigue at
medium term. On quality of life, one study investigating
the benefits of CBT compared to usual care found no
significant difference post treatment [18]. Three studies
[20-22] analysed the change in quality of life between
GET and treatment as usual, and found that the physical
function subscale improved significantly with exercise
therapy immediately post treatment. Besides studies in
which CBT and GET are compared to usual care, three
studies [23-25], compared CBT with other psychological
therapies. They provide evidence that CBT was more ef-
fective in reducing the severity of fatigue symptoms in
CFS patients post treatment, but the evidence of
medium- and long-term follow-up was inconsistent [18].
In three other studies [26-28] CBT was compared to
GET and showed a lack of difference between both treat-
ments in reducing fatigue levels at post-treatment and at
medium-term follow-up [18]. In the randomised trial of
White et al. [28], CBT and GET were compared with
adaptive pacing therapy (APT) and specialist medical
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care (SMC) alone. Participants had less fatigue and bet-
ter physical function after CBT and GET than they did
after APT or SMC alone.
Although several studies have shown positive effects on
reducing fatigue severity after treatment, some CFS patient
groups are negative about CBT, as well as GET [29,30].
At this time, most treatments are targeted towards one
or two aspects of the complaints, but various experts
[8,18,31] recommend using CBT in combination with
other interventions or in a multidisciplinary setting in
order to increase treatment effectiveness. To date, only a
few studies have reported results of a multidisciplinary
approach in peer-reviewed scientific journals. Two un-
controlled studies among young people [32,33] reported
positive effects of multidisciplinary interventions. Viner
et al. (2004) [32] assessed the outcome of multidisciplin-
ary rehabilitation group treatment (graded activity/exer-
cise programme, family sessions and supportive care)
compared with supportive care alone. Results showed
positive effects of multidisciplinary rehabilitation treat-
ment on wellness, school attendance and severity of fa-
tigue. A study by Voet et al. (2007) [33] in adolescents
with chronic pain and fatigue also showed strong posi-
tive effects on fatigue severity, school/work attendance
and general health after multidisciplinary rehabilitation
treatment. In an uncontrolled study, Torenbeek et al.
(2006) [34] evaluated a multidisciplinary group program
with a combination of clinical and outpatient treatment
in a rehabilitation centre. Patients were coached by a re-
habilitation physician, psychologist, physical therapist,
social worker, occupational therapist, exercise and sports
coach, and a group leader. Positive effects were found on
fatigue severity, experienced impairments and physical
functioning, post treatment. In another uncontrolled
pilot study of Vos-Vromans (2005) in Revant Rehabilita-
tion Centre Breda, in which the MRT was evaluated
among 36 patients, the results were promising: fatigue
severity and the impact of disease on emotional and
physical functioning decreased significantly post treat-
ment and persisted 12 months after start of treatment.
Although the results of these studies are promising, con-
clusions should be drawn carefully, because all studies
were uncontrolled. None of the above studies included
information about the cost-effectiveness of multidiscip-
linary rehabilitation treatment, which might facilitate the
decision process regarding treatment selection for practi-
tioners as well as policy makers. Therefore, these find-
ings need to be confirmed in randomised controlled
trials including an economic evaluation.
In summary, CBT is the most effective treatment at
this time; therefore, CBT needs to be compared with a
multidisciplinary rehabilitation approach to investigate
which treatment is the most effective and most cost-
effective. Because effects of CBT on quality of life and
other secondary outcomes in the medium and long term
are inconclusive, more research is needed to examine
how to sustain the treatment effect.
Aims of the study
The FatiGo trial is designed to address the following
primary objectives:
1. To assess the differences in treatment effect (change
between baseline and 6-month follow-up in fatigue
severity and quality of life) in patients with CFS
between individual multidisciplinary rehabilitation
treatment (MRT) and individual cognitive
behavioural therapy (CBT).
2. To assess the differences in long-term treatment
effect (change between baseline and 12-month
follow-up in fatigue severity and quality of life)
in patients with CFS between the two
treatments.
3. To assess the difference in cost-effectiveness and
cost-utility between MRT and CBT from both a
health care and societal perspective at 12-month
follow-up.
4. To assess the differences in treatment effect in
psychological symptoms, self-efficacy, causal
attributions, present-centred attention-awareness,
impact of disease on physical and emotional
functioning, self-rated improvement and life
satisfaction between MRT and CBT (at 6- and
12-month follow-up).
The secondary objectives of this trial are:
1. To assess the influence of patients treatment
expectancy and credibility on the effectiveness of
treatment.
2. To assess what baseline factors (other than the
assigned treatment) predict a change in fatigue and
increase in quality of life in all participants.
3. To evaluate whether changes in self-efficacy,
changes in causal attributions and/ or changes in
present-centred attention-awareness (at baseline, 6
and 14 weeks after start of treatment) mediate
changes in fatigue severity and changes in quality of
life after treatment.
Hypotheses on the primary objectives
(1)MRT is more effective than CBT in reducing fatigue
severity and increasing quality of life 6 months after
start of treatment.
(2)MRT is more effective than CBT in reducing fatigue
severity and increasing quality of life 12 months
after start of treatment.
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(3)MRT is more cost-effective than CBT when data on
medical and non-medical costs are compared over
a 12-month period and shows a higher
cost-utility.
(4)MRT is more effective than CBT in increasing
self-efficacy, non-physical attributions, present-centred
attention-awareness and life satisfaction, and is more
effective in decreasing the impact of disease on
physical and emotional functioning and decreasing the
psychological symptoms. Self-rated improvement is
significantly higher in MRT than in CBT (at 6- and
12-month follow-up).
Methods
Design
A two-arm, pragmatic, randomised, multi-centre con-
trolled trial of patients with CFS, with follow-up of 1 year
(see Figure 1). The RCT includes both an effectiveness
study as well as an economic evaluation.
Setting
The study takes place in The Netherlands in four rehabili-
tation centres: Revant Rehabilitation Centre Breda (RRCB),
Rehabilitation Centre Blixembosch in Eindhoven (RCB),
Reade Centre for Rheumatology and Rehabilitation in
Amsterdam (RCRR) and Adelante Rehabilitation Centre in
Hoensbroek (ARC). Patients are referred to the trial by
their general practitioner or a medical specialist. Patients
are treated individually in an outpatient setting.
Ethical approval
Ethical approval for the FatiGo trial was provided by the
Research Ethics Committee of Rotterdam (reference
2008/22).
Assessed for eligibility
Preselection by 
questionnaire
Intake rehabilitation physician/ 
psychologist
Excluded
Baseline assessment
(T1) 
Randomisation
CBT MRT
End of treatment assessment at 6 months
(T4)
Follow-up assessment at 12 months
(T5)
Mid-treatment assessment at 6 and 14 weeks
(T2, T3)
Excluded
Excluded
Figure 1 Flowchart of trial design.
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The participants – inclusion and exclusion criteria
Subjects are patients with CFS referred to RRCB,
RCRR, RCB and ARC. Patients are included if the fol-
lowing inclusion criteria are met:
1. The participant has given written informed consent.
2. The participant meets the CDC- 94 criteria for CFS.
3. The Checklist Individual Strength (CIS)-fatigue score
is 40 or more.
4. The participant is willing to participate in a
treatment that is set up to change behaviour.
5. The participant is aged between 18 years and
60 years old.
6. The participant is able to speak, understand and
write the Dutch language.
Exclusion criteria are:
1. Any medical condition that can explain the presence
of chronic fatigue.
2. A psychotic, major or bipolar depressive disorder
(but not an uncomplicated depression).
3. Dementia
4. Anorexia or bulimia nervosa
5. Alcohol and/or drug abuse
6. Severe obesity (BMI≥ 45)
7. Pregnancy
8. Previous or current CBT or MRT with regard to CFS.
9. More than 1 h travelling time to the nearest
participating rehabilitation centre.
Screening for participation
When a patient is referred to one of the four rehabilitation
centres, the research assistant screens the information pro-
vided by the referring general practitioner or medical spe-
cialist. The research assistant sends the patient information
on the study and asks the patient to fill in the Checklist
Individual Strength to measure fatigue and the Anxiety and
Depression Scale (HADS) [35]. If the patient has a CIS fa-
tigue score of 40 or more, the patient is invited for an intake
with the rehabilitation physician. All patients are screened
by a rehabilitation physician to check the in- and exclusion
criteria. The rehabilitation physician will verify whether an
extensive physical examination and laboratory research
according the guidelines for chronic fatigue syndrome by
the Dutch Diagnostic Compass [36] have been done by a
general practitioner, consultant in internal medicine, neur-
ologist or psychiatrist to exclude any underlying illness. If
the rehabilitation physician needs a second opinion to de-
cide whether a patient meets the in- or exclusion criteria or
when the HADS depression score is 11 or higher, an intake
with a psychologist is planned.
The rehabilitation physician explains the procedures of
the study, and if someone meets the inclusion criteria and
does not meet the exclusion criteria, he asks the patient to
sign a (written) agreement. The research assistant contacts
the patient after 1 week to make an appointment for
signing the informed consent form and for the baseline
assessment.
The interventions
The two interventions to be compared, MRT and CBT,
take 6 months to complete.
Three elements are incorporated in both treatment
groups:
1) Modification of dysfunctional beliefs regarding illness
symptoms and activity, and development of more
adequate and effective coping strategies.
2) Gradual increase of activities.
3) Normalisation of sleep/wake rhythm.
These elements are incorporated in both treatments in
a different way (see below).
Individual cognitive behavioural therapy (CBT)
CBT is a psychotherapeutic approach in which elements
of behavioural therapy and cognitive therapy approaches
are incorporated. In CBT, a model of perpetuating cogni-
tions and behaviour of CFS [14] is used to explain the per-
sistence of CFS. This model shows that high physical
attributions will decrease physical activity and increase fa-
tigue and functional impairment. This model also explains
that a low level of sense of control over symptoms and fo-
cusing on physical sensations have a direct causal effect on
fatigue severity and functional impairment. A perceived
lack of social support also increases the fatigue severity
and functional impairment. These perpetuating factors
(high physical attributions, decreased physical activity, low
level of sense of control, focusing on physical sensations
and perceived lack of social support) are the focus of the
intervention in CBT [37,38].
CBT is divided into three phases:
1) Intake
2) Gradual reactivation
3) Prevention of relapse
1) Intake
During the intake phase (four sessions in
4 weeks), the cognitive behavioural therapist gets
acquainted with the patient. The patient is asked
about: the cause and course of the complaints,
the present complaints, illness beliefs and illness
behaviour, coping, social interactions/
participation, and the expectations and personal
goals of the patient. The therapist tries to
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determine the patient’s activity level by asking
about activities during the day and week, and
categorises the patient into a relatively active
patient or a patient with a low activity pattern.
The therapist explains the model of perpetuating
cognitions and behaviour of CFS, and how to
overcome CFS by changing patterns of thinking
and changing behaviour.
2) Gradual reactivation
– Graded exercise therapy (GET) is used to
gradually increase physical activity. The patient
follows a schedule to gradually increase activities
at home (walking and bicycling). The schedule is
provided by the therapist in accordance with the
patient’s personal goals. The patient has to
increase his/her activities at home and receives
feedback afterwards during the next therapy
session. If needed, schedules are made to increase
social and/or mental activities as well. Another
important subject during gradual reactivation is
the balance between different activities and the
patient’s personal responsibility to see to it.
– In the dialogues with the therapist and by doing
exercises at home, the patient is taught to change
negative beliefs regarding symptoms of fatigue,
self-expectations and self-esteem. Specific lifestyle
changes are encouraged if deemed appropriate.
– Sleep/wake rhythm: the patient is encouraged to
change the sleep/wake rhythm immediately at the
start of treatment into a regular sleep/wake
rhythm. Sleeping during the day is not allowed.
– In accordance with the principles of GET, a plan
to return to work will be made.
3) Prevention of relapse:
If activities are increased and the sleep/wake
rhythm is normalised, the patient is encouraged
to unsettle him-/herself and to cope with these
disturbances by applying the things he/she
learned during therapy. Personal goals are
evaluated and relapse prevention is addressed.
The patient assigned to this group will attend 16
individual therapy sessions, spread out over
6 months with a psychologist or behavioural
therapist. The first 6 weeks, the patient has
weekly contact with the therapist, followed by
once every 2 weeks for the next 20 weeks. The
CBT protocol is fixed and different for relatively
active patients and patients with a low activity
pattern [37,38]. In the treatment for the relatively
active patient, the patient learns to spread out
activities during the day and to vary different
activities during the day. The patient learns to be
active within physical and mental boundaries to
overcome overburdening. With the use of
cognitive therapy, cognitions and behaviour that
may lead to overburdening (like not accepting
boundaries in activity, and having high
expectations) are the primary focus of treatment.
After reaching the baseline (without peaks in
complaints of the CFS) there will be a gradual
increase of activities. For patients with a low
activity pattern, activities will be increased from
the beginning of therapy.
Individual multidisciplinary rehabilitation treatment (MRT)
In multidisciplinary treatment, a biopsychosocial model of
CFS is used including biological, physical and psychosocial
aspects [10,31]. In the biopsychosocial model of CFS various
precipitating, predisposing and perpetuating factors are
merged, suggesting that multiple pathways may lead to the
causation and persistence of CFS [31]. The protocol of the
MRT is not fixed, but varies between patients, depending
on the relation between treatable components (precipitat-
ing, predisposing and perpetuating factors), present com-
plaints and personal needs of a patient. The focus of
treatment can be different for each patient depending on
these relations. During treatment every therapist fills in
treatment checklists for every patient to register which
methods are used.
MRT is divided into three phases:
1) Observation
2) Treatment
3) Prevention of relapse
1) Observation
During a 2-week observation, therapists
(psychologist, social worker, physical therapist
and occupational therapist) get acquainted with
the patient. During observation, they ask the
patient about: the cause and course of the
complaints, the present complaints, illness beliefs
and illness behaviour, coping, the social
environment the patient lives in, expectations and
personal goals. The psychologist (two 1-h
sessions) further elaborates on the psychological
history, present psychological wellbeing, use of
medical care including medication, stress factors,
cognitions, attitudes and mood (state of mind).
The social worker (two 1-h sessions) assesses the
social context in which the patient lives
(relationships, family and role in a family), work
situation and communication. The physical
therapist (five 30-min sessions) makes an
estimation of the physical condition and the
patient’s body awareness. The occupational
therapist (four 30-min sessions) aims at
ergonomics, lifestyle, day/week schedule and the
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variety of activities during the day/week. During
observation, the treatable components are
weighted in relation to the present complaints. If
a strong relation exists between these
components and the present complaints, these
components will be addressed during treatment.
In a team meeting, therapists and the
rehabilitation physician discuss the components
and methods that will be used during the
treatment phase. The rehabilitation physician will
discuss the conclusions of this meeting with the
patient and ask for commitment to the proposed
therapy. A treatment contract will be signed by
the rehabilitation physician and the patient.
2) Treatment
Two weeks after ending the observation phase, the
treatment phase starts. This phase takes 10 weeks
to complete. Depending on the patient goals/needs
and the relation between treatable components and
present complaints, different methods will be more
or less used in the treatment phase. The following
methods can be incorporated:
– Body awareness therapy [39,40]: aims to establish an
increased awareness and consciousness of the body
and its relation to psychological wellbeing. The
patient learns to discriminate bodily symptoms
other than fatigue and pain and learns to react on
these healthy bodily symptoms. The patient will be
coached by a physical therapist. Bodyscan,
grounding, awareness exercises of the influence of
thoughts and emotions on the body are some of the
exercises that will be practised during treatment. In
the end, the patient will be aware of the relation
between the body, its physical function,
psychological wellbeing and social interaction, and
is able to react on stress in an appropriate way.
– Cognitive behavioural therapy: A
psychotherapeutic approach in which elements of
behavioural and cognitive therapy approaches are
incorporated. CBT facilitates the identification of
unhelpful, negative emotion-provoking thoughts,
dysfunctional emotions, behaviours and cognitive
patterns, and challenges them through a goal-
oriented, systematic procedure. The patient learns
to identify negative beliefs regarding the
symptoms of fatigue, self-expectations or self-
esteem, and is encouraged to challenge and
change them into new, more realistic, more
helpful alternatives.
– Gradual reactivation: At the start of treatment,
activities are trained time contingent under close
supervision of the physical therapist and
occupational therapist. The patient follows
schedules to gradually increase activities and
receives immediate feedback during treatment
when needed. The schedules of fitness exercises
and swimming are provided by the physical
therapist in accordance with the patient’s personal
goals. Another schedule is provided by the
occupational therapist in accordance with the
patient’s personal goals to increase activity and vary
activities at home. In the final phase of treatment,
schedules are of less importance and the patient is
encouraged to increase activities on his/her own
without following a schedule (see pacing).
– Pacing: During the second phase of treatment,
the patient is taught to pace his/her activities
during the day/week. By developing awareness of
healthy bodily symptoms the patient will be able
to balance his/her activities (psychological as well
as physical activities) before extreme fatigue or
pain prevails. The schedule of time-contingent
increase is no longer followed. The patient will
pace his/her activities based on his/her own
experiences.
– Principles of mindfulness. Mindfulness is a non-
elaborative, non-judgemental, present-centred
awareness in which each thought, feeling or
sensation that arises is acknowledged and
accepted as it is. The patient learns to self-regulate
attention that is maintained on immediate
experience, thereby allowing for increased
recognition of mental events in the present
moment. They also learn to observe the thoughts,
emotions and sensations that arise, without making
judgements about their truth, importance or value,
and without trying to escape, avoid or change
them. Regular practice of mindfulness skills
increases self-awareness and self-acceptance,
reduces reactivity to passing thoughts and
emotions, and improves the ability to make
adaptive choices [41]. In patients who have been
chronically ill, mindfulness skills have a positive
effect on depression, mood and activity level [42].
– Normalising of the sleep/wake rhythm. The
sleep/wake rhythm will be discussed and with a
schedule of 4 weeks will be gradually changed to
the sleep/wake rhythm the patient desires.
Sleeping during the day will be stopped
immediately. If there are problems with the
quality of sleep, principles of sleep hygiene are
prescribed by the psychologist. Relaxation
therapy is used to increase the efficiency of the
resting moments during the day and to improve
the quality of sleep during the night if needed.
– Social reintegration. Under supervision of the
occupational therapist and social worker, the
patient is coached to reintegrate into society by
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making a plan to return to his/her work or
school, and to increase their social activities.
3) Prevention of relapse
Six weeks after ending the treatment phase, the
patient will visit the social worker. Thirteen weeks
after ending the treatment phase, the patient will
visit two therapists of his/her choice who were
involved in the previous treatment. Both after-
care visits are used to stimulate and motivate the
patient to practice at home what he/she has
learned during the treatment phase.
Although MRT and CBT have three corresponding
aims—modification of dysfunctional beliefs, gradual in-
crease of activities and normalisation of sleep/wake
rhythm—many differences can be detected between the
two treatments. The main differences are viewed in
Table 1.
Training the therapists to deliver the interventions
Four rehabilitation teams deliver the multidisciplinary
rehabilitation treatment. Each team consists of one or
two rehabilitation physicians or physician assistants
(under supervision of a rehabilitation physician), one or
two psychologists/behavioural therapists, two social
workers, two physical therapists and two occupational
therapists. Six other psychologists/cognitive behavioural
therapists deliver the cognitive behavioural therapy in
the four participating rehabilitation centres. The psy-
chologists of the CBT group are not involved in the
multidisciplinary rehabilitation treatment and meetings
with a supervisor will be organised separately for both
groups of psychologists.
CBT
All psychologists and behavioural therapists are trained
in CBT. A 3-day workshop before the start of the study
was held, guided by an external CBT expert, who is
acquainted with the CBT protocol [38,43] to ensure
that execution of CBT is similar and up to standard in
each centre. During the trial seven supervision meet-
ings are organised in which audiotaped sessions pro-
vided during the trial are used to evaluate the therapy.
Therapists are free to contact their supervisor when
questions arise.
MRT
Before the beginning of the study, the therapists of RRCB,
who work with the protocol for at least 5 years, organised
separate workshops for each involved discipline and a
multidisciplinary team meeting in which the therapists got
acquainted with the MRT protocol. During the trial two
disciplinary supervision meetings and two multidisciplin-
ary team supervision meetings will be held. Therapists are
free to contact their supervisor when questions arise.
Recruitment of patients
The inclusion of new patients took place from November
2008 until January 2011. Potential referrers of patients to
the four rehabilitation centres were informed about the
developments of the trial by newsletters four times during
the trial. Several articles on Internet sites and in magazines
of patient support groups were published to inform patients
about the trial and how they could be referred.
Outcome measures
Primary outcome measures
Primary outcome parameter:
Fatigue severity is assessed by a subscale of the Checklist
Individual Strength (CIS) [44,45]. The subscale consists
of eight items, each scored on a 7-point Likert scale
(range 8–56). Validity and reliability of the scale are good
[44,46].
Quality of life is assessed by the Short-Form 36 (SF-36)
[47]. The SF-36 has eight subscales: physical functioning
(10 items), role-physical (4 items), bodily pain (2 items),
general health (5 items), vitality (4 items), social
functioning (2 items), role-emotional (3 items) and mental
health (5 items). Every subscale is transformed into ratings
on a scale of 0 (limited in all activities) to 100 (able to
carry out vigorous activities). The validity and reliability of
every subscale are high [48].
Secondary outcome measures
Secondary outcome parameters are:
1. Psychological symptoms will be measured with the
Symptom Check List-90 (SCL-90). The SCL-90 is a
multidimensional questionnaire designed to screen
for a broad range of psychological problems. The
Table 1 Differences between CBT and MRT
CBT MRT
Treatment focus on perpetuating factors Treatment focus depending on the relation between the (precipitating,
predisposing and perpetuating) factors and the presented complaints.
Afterwards feedback at next therapy session Immediately feedback during therapy
Pays no attention to physical sensations Stimulating awareness of healthy bodily symptoms
CBT CBT incorporated with principles of mindfulness
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questionnaire consists of 90 items. Each item is
scored on a 5-point Likert scale (0 is ‘not at all’ and
4 is ‘extremely’) [45,49]. The items are combined in
the following primary symptom dimensions:
somatisation, obsessive-compulsive, interpersonal
sensitivity, depression, anxiety, anger-hostility,
phobic anxiety, paranoid ideation and
psychoneuroticism (total score of the SCL-90). The
validity and discriminating validity are good [50].
2. Self-efficacy will be measured with the Self-Efficacy
Scale-28 (SES 28) to compare sense of control in
relation to CFS complaints [25,45]. The scale
consists of seven questions. Items are scored on a
4-point Likert scale. The total score ranges from 7 to
28. A higher score means more sense of control.
3. Causal attributions will be measured with the Causal
Attribution List (CAL) [25]. The CAL assesses
whether the patient is likely to attribute complaints
to physical or non-physical causes. The list consists
of ten questions scored on a 4-point Likert scale.
Total subscale scores of physical and non-physical
attributions range from 5 to 20. A higher score
indicates a stronger conviction.
4. Present-centred attention-awareness, which is
foundational to mindfulness, will be measured with
the Mindfulness Attention Awareness Scale (MAAS)
[51]. The validity and reliability of the Dutch version
of the MAAS are good [52]. The MAAS consists of
15 statements scored on a 6-point Likert scale. The
mean total score ranges from 1 to 6. A higher score
indicates a greater awareness of present experiences.
5. A patient’s personal treatment goals will be measured
with the Patient-Specific Complaints and Goals
questionnaire (PSCG) [53]. The patient selects three
activities that he/she perceives as important in his/her
daily life and wants to improve. The patient rates the
performance of the activity on a 100-mm visual
analogue scale (VAS). The left side of the VAS is
marked as ‘no problems at all’. On the right side the
VAS is marked ‘impossible’. The PSCG is a valid and
reliable measure with sufficient responsiveness [53].
6. Sickness Impact Profile-8 will be used to measure
the impact of disease on both physical and emotional
functioning [54]. The SIP-8 is derived from the SIP.
The SIP8 has eight subscales: home management,
mobility, alertness behaviour, sleep/rest, ambulation,
social interaction, work, and recreation and
pastimes. Psychometric research has indicated that
the SIP is reliable and valid [55,56].
7. Physical activity will be measured by a multisensor
armband (Sense Wear Pro Armband; BodyMedia,
Inc., Pittsburgh, PA). The armband was developed to
measure energy expenditure by integrating
accelerometry with multiple physiologic sensors
including galvanic skin resistance, heat flux, body
temperature and near body ambient temperature.
The armband is worn 7 consecutive days on the
right upper arm over the triceps muscle and
monitors various physiological and movement
parameters. The armband provides a reproducible
and accurate measure in subjects with chronic illness
with moderate functional limitations [57].
8. Six questions are used to measure self-rated
improvement after therapy and the satisfaction of
the patient. The questions: ‘How satisfied are you
with the effect of treatment’? ‘Is there a difference in
how you handle problems now compared to before
treatment started?’ and ‘Is there a difference in your
daily activities now compared to your situation
before treatment started?’ are scored on a 5-point
Likert scale (‘1’ is very content/much improvement
and ‘5’ is very discontented/situation is worse). The
question: ‘To what extend did you achieve your
personal treatment goals?’ is scored on a 10-point
Likert scale, range 1–10. The questions: ‘Would you
recommend the treatment to other CFS patients?’
can be answered with ‘yes’, ‘no’ or ‘I don’t know’. The
question: ‘Do you still consider yourself a CFS
patient?’ can be answered with ‘yes’ or ‘no’ [58].
9. Life satisfaction will be measured by the Life
Satisfaction Questionnaire, Dutch version (LSQ-DV).
The LSQ-DV has one question on general life
satisfaction and eight questions about domain-specific
life satisfaction: self-care ability, leisure situation,
vocational situation (including housekeeping), financial
situation, sexual life, partner relationship, family life,
contacts with friends and acquaintances. Questions are
answered on a 6-point Likert scale (‘1’ is very
dissatisfied, ‘6’ is very satisfied). The reliability of the
LSQ-DV has been proven to be moderate to good for
most domains in a patient group with chronic illness
[59].
10.Quality of life and utilities (health-related quality of
life) will be measured by means of the standard
Dutch version of the EuroQol (EQ-5D) [60]. The
EQ-5D contains five dimensions of health-related
quality of life, namely mobility, self-care, daily
activities, pain/discomfort and depression/anxiety.
Each dimension can be rated at three levels: no
problem, some problems and major problems. The
five dimensions can be summed into a health state.
Utility values are calculated for these health states,
using preferences elicited from a general population,
the so-called Dolan algorithm [61]. The utility values
derived from the Dolan algorithm will be used to
compute Quality Adjusted Life Years (QALYs). The
Dolan algorithm has been established using a
general population from the UK. Also a Dutch
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algorithm has become available that will be used in
the sensitivity analysis [62].
Treatment expectancy and credibility
Patients’ initial beliefs about the success of a given treat-
ment have been shown to have an important influence on
the final treatment outcome. A study by Smeets et al.
(2008) [63] found evidence of predictive validity of expect-
ancy and credibility scored by patients with chronic low
back pain before following different active interventions
To measure treatment expectancy and credibility, 2 weeks
after the start of treatment, all participants will be asked
to fill in the Dutch version of the Devilly and Borkovec
questionnaire [64].
Mediation
In order to understand how treatment works, mediation
analyses are performed. Two studies on mediation could
not confirm the mediating role of physical activity in redu-
cing fatigue in CFS. Moss-Morris (2005) [21] investigated
physical activity as a mediator in the treatment effect of
GET and Wiborg (2010) [65] in CBT. Since physical activity
does not mediate the outcome, other parameters have to be
responsible for a decrease of fatigue during therapy. In the
model of Vercoulen et al. [14], somatic attributions, focus-
sing on pain and fatigue, and low self-efficacy contribute to
the perpetuating of CFS complaints. Patients with CFS feel
helpless and surrendered to their complaints, making it dif-
ficult to change their situation. During therapy patients
learn to change cognitions into more helpful cognitions,
which increases self-efficacy. They learn to accept their situ-
ation in the present, making choices based on helpful cog-
nitions and bodily symptoms other than pain and fatigue,
and learn to focus on getting better instead of focussing on
complaints and somatic attributions. Our hypothesis is that
by increasing self-efficacy, decreasing somatic attributions
and increasing the present-centred attention-awareness
during activities first, behavioural changes can be made
based upon these changes and eventually the severity of
fatigue will decrease.
There are no studies that we are aware of that determine
the mediating role of self-efficacy, somatic attributions
and present-centred attention-awareness. Mediation will
be investigated by the three-step method described by
Baron and Kenny [66]. Before treatment (T1), 6 and
14 weeks after start of treatment (T2, T3), CIS, SE28, CAL
and MAAS are filled in by the patient in order to analyse
mediation at different moments during treatment phase.
Cost analysis
The Trimbos/iMTA questionnaire for Costs associated with
Psychiatric Illness (Tic-P) will be used to measure treat-
ment costs and additional expenses [67]. The subsection on
absence from work (productivity loss by absenteeism and
by loss of productivity while at work, and informal care and
domestic help) is filled in every month. The subsection on
health care costs (medical treatments, paramedic therapy,
alternative therapy, self-care groups, clinical or outpatient
treatment in hospital and other institutions, and medica-
tion) is filled in every 3 months. Treatment hours are regis-
tered by the therapists and the rehabilitation physicians in
checklists filled in after each treatment session. The valu-
ation of health-care costs, patient and family costs will be
based on the updated Dutch manual for cost analysis in
health-care research [68]. For care for which no costs-
guidelines are available, estimations of the costs will be
made based on the real costs or on population-based esti-
mates from the literature.
Assessment and procedures
After inclusion, the research assistant contacts the patient
to make an appointment for the baseline assessment (T1).
During T1 the patient is asked to wear the activity monitor
for one week and to fill in the following questionnaires:
– Checklist Individual Strength (CIS)
– Short Form 36 (SF-36)
– EuroQol- 5D (EQ-5D)
– Symptom Check List-90 (SCL-90)
– Self-Efficacy Scale-28 (SES 28)
– Causal Attribution List (CAL)
– Mindfulness Attention Awareness Scale (MAAS)
– Sickness Impact Profile-8 (SIP-8)
– Life Satisfaction Questionnaire, Dutch Version
(LSQ-DV)
The patient is instructed on how to fill in the Tic-P, part II
on health- and non-health-related costs every month for
1 year. One week after baseline assessment, the research as-
sistant collects the activity monitor. The research assistant
gives the patient a blind envelope with the treatment condi-
tions. Treatments start within 4 weeks. Two weeks after the
start of treatment, a patient is asked to fill in the list of
Borkovec and Devilly and the PSCG, part 1. At 3 and
9 months after T1 a patient is asked to fill in the Tic-P, part
I at home. Six months after the start of treatment the re-
search assistant assesses the patient again (T4). The patient
is asked to wear the activity monitor and fill in the same
questionnaires as in T1 completed by the PSCG, part II
self-rated improvement questionnaire and Tic-P, part I.
Twelve months after the start of the treatment, the same as-
sessment as in T4 will be repeated (T5). For each patient
the study takes 12 months.
Randomisation
After signing the informed consent form the patients are
randomly divided into two groups: CBT and MRT. For each
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rehabilitation centre a randomisation list was generated by
computer under supervision of an independent statistician.
Before recruitment of patients an independent person pre-
pared sealed envelopes for each rehabilitation centre and
numbered them sequentially according to the randomisa-
tion list. The envelope is given to the participating patient
by an independent research assistant after baseline assess-
ment. The patient is asked not to open the envelope in front
of the research assistant. Randomisation is performed for
each centre to prevent differences between the treatment
groups in the distribution of centres.
Adverse events
Patients are able to contact a physician, who is appointed as
an independent physician for the study, at any time. Ad-
verse events will be monitored carefully. If any adverse
event occurs or a patient withdraws from treatment, the re-
searcher or research assistant will ask the patient and the
therapist(s) why the patient is withdrawing. If deterioration
is reported, the patient is offered appropriate help if needed.
Referrals to other institutions are registered. Each patient
withdrawing from treatment is asked to participate in the
follow-up measurements. Patients who are not willing to
participate in the follow-up measurements are asked to fill
in questionnaires at home without wearing the activity
monitor. Reasons for not wanting to participate in the
follow-up measurement are registered.
Analyses
Sample size
Based on the available literature [25,34,69] and our pilot
study, mean CIS-fatigue scores at the start of CBT or
multidisciplinary rehabilitation are about 50–52 with a
standard deviation of 3.9-5.9. Following previous trials
[28,34], we assume that a difference of 0.5 SD of the
mean group score at baseline is clinically relevant. This
equals a difference of about 3.0 points on the CIS fatigue
scale. With a sample size of 48 patients in each treat-
ment arm, accepting an alpha error of 0.05 and a power
of 0.80, it is possible to measure a minimal difference of
3.0 points on the CIS fatigue scale. To compensate for
an estimated 25% dropout rate, a total of 120 people will
be included.
Analyses of efficacy
The effects of therapy conditions on the various out-
comes will be compared using an ‘intention to treat’ ap-
proach. Data will be analysed with mixed linear
regression models. The follow-up measurement will be
the dependent variable, and the baseline value of the
particular outcome will be added as covariate as well as
random intercepts for individuals to allow for depend-
ence within patients and centres [70]. Effect modifica-
tion will be evaluated by introducing interactions
between therapy condition and the potential modifiers
in the equation. There will be a post-hoc analysis of the
non-response group and the missing values. Dropout
patients will be asked about the reason for stopping
treatment or not attending a measurement. Patient char-
acteristics of the dropouts will be compared to those of
the group that completed each treatment. For the ana-
lyses we will use SPSS statistical software.
Economic analyses
Health-care costs will be measured using the Tic-P.
Total costs are calculated by using an update of the
Dutch manual for costing in economic evaluations [68].
Clinical outcomes 12 months after the start of treatment
will be used in the economic evaluation. Student’s t-test
for statistical significance will be used to measure differ-
ences between MRT and CBT. Fatigue severity during
1 year of follow-up will be used as the primary outcome
measure for cost-effectiveness.
A cost-utility analysis will be performed by relating the
mean total costs to the mean health utility (EQ-5D)
scores of both groups. The costs per QALY of both
treatments will be compared. Our primary (base-case
analyses) will be performed according to the intention-
to-treat principle, including data from all participants re-
gardless of whether they received the intervention or
not. For the analyses we will use SPSS statistical software
and Excel (for the bootstraps).
Respondents for whom at least 75% of the data per meas-
urement instrument are available will be included in the
analysis. Missing data on item level will be handled using
SPSS missing value analysis. Completely missing measure-
ments will be handled using multiple imputation (MI). A
baseline analysis will be performed to examine the compar-
ability of groups at baseline for both costs and outcomes. If
necessary, methods will be applied to control for differ-
ences in baseline [71]. To investigate whether data are nor-
mally distributed, a Kolmogorov-Smirnov test will be
performed. Despite the usual skewness in the distribution
of costs, the arithmetic means will be generally considered
the most appropriate measures to describe cost data
[72,73]. Non-parametric bootstrapping is a method based
on random sampling with replacement based on individual
data of the participants [74]. The bootstrap replications will
be used to calculate 95% confidence intervals around the
costs (95% CI), based on the 2.5th and 97.5th percentiles.
If cost data are distributed normally, t-tests will be used.
The incremental cost-effectiveness ratio (ICER) will be
determined on the basis of incremental costs and the
effects of the MRT in comparison with CBT. The cost-
effectiveness ratio will be expressed in terms of costs per
unit of outcome; the cost-utility ratio will focus on the in-
cremental cost per QUALY gained. The robustness of the
ICER will be checked by non-parametric bootstrapping.
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Bootstrap simulations will also be conducted in order to
quantify the uncertainty around the ICER, yielding infor-
mation about the joint distribution of cost and effect dif-
ferences. The bootstrapped cost-effectiveness ratios will
be subsequently plotted in a cost-effectiveness plane in
which the vertical line reflects the difference in costs and
the horizontal line reflects the difference in effectiveness.
The choice of treatment depends on the maximum
amount of money the society is prepared to pay for a gain
in effectiveness, which is called the ceiling ration. There-
fore, the bootstrapped ICERs will also be depicted in a
cost-effectiveness acceptability curve showing the prob-
ability that MRT is cost-effective using a range of ceiling
ratios. Additionally, to demonstrate the robustness of our
base-case findings, a multi-way sensitivity analysis will be
performed.
Mediation analyses
In the mediation analysis, we investigate whether self-
efficacy, somatic attributions and/or present-centred
attention-awareness intervenes in the relationship be-
tween treatment and outcome. Multiple regressions are
used to explore which factors mediate the outcome. Me-
diation is suggested when the change in the putative
mediating factors is significantly related to treatment as
the independent variable, outcome is significantly related
to treatment as the independent variable, and finally, the
relationship between outcome and treatment decreases
(or goes to zero) when the change in the mediation
factor is entered into the equation [66].
Participant non-adherence with treatment
Participant non-adherence with treatment will be mea-
sured both by recording attendance and by therapist rat-
ings of adherence to therapy.
Trial management and oversight
The day-to-day management of the trial is carried out by
the principal investigator, Desirée Vos-Vromans, in con-
sultation with other members of the trial team and the
research assistants. Every rehabilitation centre has one
or two research assistants.
Discussion
Treatment facilities for patients with CFS in multidiscip-
linary rehabilitation settings are rare, because most health
insurance companies and rehabilitation centres are not
convinced of the benefit of MRT for this group. MRT in
this form is unique and has never been investigated in a
multicentre RCT. The results of the FatiGo trial will pro-
vide information on the effects of CBT and MRT, media-
tors of the outcome, cost-effectiveness, cost-utility and the
influence of treatment expectancy and credibility on the
effectiveness of both treatments in patients with CFS.
Trial status
At the time of the first submission of the manuscript,
data collection was ongoing. Currently the data collec-
tion has been completed. The data will be analysed from
May until October 2012. Results of the trial will be avail-
able in November 2012.
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